Gilead Sciences, Inc.

Daniel G Shore

Scott D Schroeder

James G Taylor

Michael Graupe

Lan Jiang

Stephen E Ammann

Jeromy J Cottell

Scott E Lazerwith

Zheng-Yu Yang

Michael L Mitchell

Eda Y Canales

Elbert Chin

Gediminas J Brizgys

Nathan E Wright

Chienhung Chou

Chao-I Hung

Suzanne M Szewczyk

Weng K Chang

Kavoos Kolahdouzan

Henok H Kinfe

Sheila M Zipfel

Julian Andrew Codelli

Yasamin Moazami

Rhiannon Thomas-Tran

James S Cassidy

Nathan D Shapiro

Christopher J Swank

The present disclosure provides GLP-1R agonists, and compositions, methods, and kits thereof. Such compounds are generally useful for treating a GLP-1R mediated disease or condition.

GLP-1R modulating compounds

The present disclosure relates generally to certain compounds, pharmaceutical compositions comprising said compounds, and methods of making and using said compounds and pharmaceutical compositions. The compounds and compositions provided herein may be used for the treatment or prevention of an autoimmune disease and/or inflammatory condition, including systemic lupus erythematosus and cutaneous lupus erythematosus.

Thienopyrrole compounds

The present disclosure provides GLP-1R agonists, and compositions, methods, and kits thereof. Such compounds are generally useful for treating a GLP-1R mediated disease or condition in a human.

Growing community of inventors

San Mateo, CA, United States of America

Daniel G Shore